What Makes Suboxone Film Different from Other Oral Medications
Most oral medications are swallowed as tablets or capsules, passing through the mouth quickly and having minimal sustained contact with tooth surfaces. Suboxone sublingual film is fundamentally different: patients are instructed to place the strip under the tongue or against the cheek and allow it to dissolve completely — a process that takes several minutes. During dissolution, the film releases all of its components directly into the oral environment, including acidic excipients added to stabilize the formulation and aid dissolution. The most significant of these is citric acid.
Citric acid has a pKa of 3.1 and can lower local oral pH to approximately 3.4 to 4.0 during film dissolution. The critical pH threshold for enamel demineralization — the process by which acid dissolves the mineral hydroxyapatite in tooth enamel — is approximately 5.5. At the pH levels created by dissolving Suboxone film, enamel dissolution occurs actively throughout each dosing episode. For a patient taking two film strips daily, this represents more than 700 significant enamel acid attacks per year.
The Pattern of Damage: Why It Looks Different from Ordinary Decay
Ordinary bacterial tooth decay tends to develop in specific locations where plaque accumulates — pits and fissures on chewing surfaces, contact points between teeth, and areas near the gumline. Acid erosion from Suboxone produces a different pattern: smooth, cupped, or dished lesions that affect the facial (front-facing) and lingual (tongue-facing) surfaces of teeth, which are not typical sites for bacterial decay. Dentists who are aware of the Suboxone dental injury pattern can identify this characteristic morphology in X-rays and clinical examination and document it in treatment notes.
The damage also tends to be unusually widespread and rapid. Patients often describe all of their teeth deteriorating simultaneously, within months to a couple of years of starting Suboxone. This generalized, rapid progression is inconsistent with ordinary dental disease — even patients who acknowledge suboptimal hygiene typically do not develop cavities across all teeth at once. The generalized and accelerated nature of the damage is a key piece of evidence connecting the injury to Suboxone rather than patient behavior.
Buprenorphine's Effect on Saliva — A Compounding Factor
Buprenorphine, the active ingredient in Suboxone, can cause xerostomia (dry mouth) as a side effect. Saliva is the mouth's primary defense against acid erosion — it buffers acids, remineralizes early enamel damage, and washes away food and bacteria. Dry mouth significantly reduces these protective functions, amplifying the damage caused by the acidic film excipients. The combination of direct acid exposure from the film plus reduced salivary protection from the drug's side effects creates a particularly damaging environment for tooth enamel.
Frequently Asked Questions
Related Pages
Suboxone Statute of Limitations by State
Suboxone dental injury claims are subject to state product liability statutes of limitations, typically 2 to 3 years, which may run from the January 12, 2022 FDA safety communication under the discovery rule. Deadlines vary significantly by state and individual circumstances — time is critical and consultation with an attorney is the only reliable way to determine your specific deadline.
Suboxone Dental Records and Evidence Gathering
Dental records — including clinical notes, X-rays, and billing documentation — are the evidentiary foundation of every Suboxone dental injury claim. Gathering them promptly is critical because dental practices have limited record retention requirements and older records may be unavailable from closed or sold practices.
Suboxone Settlement Amounts and Expectations
Reported Suboxone dental injury settlements have ranged from approximately $35,000 for minor-to-moderate cases to $250,000 or more for complete tooth loss requiring full-mouth reconstruction. The MDL is ongoing and no global settlement has been announced — individual case values depend heavily on injury severity, documentation quality, and state-specific legal factors.
Indivior's Failure to Warn
Indivior, the manufacturer of Suboxone, had access to medical literature and adverse event data establishing the dental risk of its sublingual film formulation for years before adding dental warnings to its label. Under pharmaceutical product liability law, this gap between knowledge and disclosure forms the foundation of the failure-to-warn claims at the center of Suboxone dental injury litigation.
The FDA Suboxone Dental Warning — January 2022
On January 12, 2022, the FDA issued a formal drug safety communication confirming that buprenorphine medicines dissolved in the mouth — including Suboxone film — can cause severe dental problems. The FDA reviewed 305 adverse event reports and found widespread, serious dental injuries requiring extractions, root canals, and full reconstruction. This communication is legally significant as the potential trigger date for the statute of limitations under the discovery rule for thousands of patients.
Suboxone Dental Injury Qualification Criteria
Not every Suboxone user who experienced dental problems has a viable legal claim. Qualifying cases generally involve significant dental injuries — multiple cavities, extractions, tooth loss, or reconstruction — developed during Suboxone use, documented in dental records, and timely filed. Understanding the criteria helps patients determine whether to pursue a claim.
Suboxone vs. Generic Buprenorphine Film
The dental injury risk from buprenorphine sublingual film is not unique to the Suboxone brand — generic buprenorphine/naloxone sublingual films share the same acidic excipient mechanism and the same dental injury profile. However, pursuing claims against generic manufacturers involves different legal considerations than brand-name product liability claims under both federal and state law.
Suboxone Dental Treatment Costs
Dental rehabilitation costs for Suboxone-related injuries can range from several thousand dollars for restorations to $80,000 or more for full-mouth implant-supported reconstruction. These documented costs form the economic damages component of a claim and are recoverable in litigation. Understanding the cost breakdown helps patients evaluate the potential value of their claim.
How to File a Suboxone Dental Injury Lawsuit
Filing a Suboxone dental injury lawsuit begins with gathering dental and prescription records, consulting a pharmaceutical litigation attorney, and submitting a complaint. Most cases are filed in or transferred to MDL 3092 in the Northern District of Ohio. The process is handled almost entirely by the attorney, with no upfront costs under a contingency fee arrangement.
Suboxone Class Action vs. Individual Claims
Suboxone dental injury litigation is structured as a multidistrict litigation (MDL), not a class action. In an MDL, plaintiffs retain individual claims and individual damages — each client's recovery is based on their specific injuries, not shared with others. Understanding this distinction helps plaintiffs know what to expect from the process.
MAT Patients and Dental Stigma
People in recovery from opioid use disorder who experienced Suboxone-related tooth loss face a unique double stigma: societal bias against addiction, and the unfair association between visible tooth loss and substance use. These psychological and social harms are legally compensable non-economic damages, and addressing them with compassion and dignity is central to how these cases should be litigated.
Suboxone Tooth Decay Lawsuit
Suboxone sublingual film strips — a medication-assisted treatment (MAT) for opioid use disorder — dissolve under the tongue and contain citric acid and other acidic excipients that, with repeated use, erode tooth enamel and cause rapid, severe dental decay. Thousands of patients who faithfully took Suboxone as prescribed to manage opioid dependence later discovered they had lost multiple teeth, required extensive dental reconstruction, or faced thousands of dollars in oral surgery costs — through no fault of their own. Manufacturer Indivior (formerly part of Reckitt Benckiser) knew or should have known about these dental risks for years but failed to include adequate warnings on the product label. The FDA confirmed the danger with a formal safety communication on January 12, 2022, requiring updated product labeling. Patients who suffered dental injuries while using Suboxone sublingual film may have valid product liability claims against Indivior for failure to warn.
View full case overview